CompletedPHASE2, PHASE3NCT02143973
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Studying Uremic pruritus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Trevi Therapeutics
- Principal Investigator
- Chief Development OfficerTrevi Therapeutics
- Intervention
- nalbuphine HCl ER(drug)
- Enrollment
- 167 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2016
Study locations (30)
- Nephrology Associates PC, Birmingham, Alabama, United States
- University South Alabama Medical Center, Mobile, Alabama, United States
- Arizona Kidney Disease and Hypertension Center, Phoenix, Arizona, United States
- U.S. Renal Care Inc., Pine Bluff, Arkansas, United States
- North America Research Institute, Azusa, California, United States
- Pegasus Dialysis Center, Bakersfield, California, United States
- Central Nephrology Medical Group, Bakersfield, California, United States
- Mark Lee MD, Inc, Whittier, California, United States
- Nephrology and Hypertension Associates PC, Middlebury, Connecticut, United States
- Pines Clinical Research, Pembroke Pines, Florida, United States
- Genesis Clinical Research, Tampa, Florida, United States
- DaVita Central Orlando Dialysis, Winter Park, Florida, United States
- Southwest Georgia Nephrology Clinic PC, Albany, Georgia, United States
- Renal Physicians of Georgia, Macon, Georgia, United States
- Pacific Renal Research Institute, Meridian, Idaho, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02143973 on ClinicalTrials.govOther trials for Uremic pruritus
Additional recruiting or active studies for the same condition.